inspiring canadians to live better.

healthing leaf

inspiring canadians to live better.

healthing leaf
get healthing in your inbox with the morning checkup and weekender newsletter!

study shows new obesity drug may be even more effective than current therapies

the drug in question, tirzepatide, is a dual gip and glp-1 receptor agonist that works by tweaking certain hormones involved in insulin secretion and improving the body’s ability to use insulin.

by angelica bottaro
published dec 11, 2024
read time 4 minute read
join the conversation
read time 4 minute read
join the conversation
the surmount-5 phase 3b trial monitored patients on both semaglutide and tirzepatide and found that at the end of the trial, tirzepatide led to a 47 per cent greater weight loss than semaglutide. getty images
weight loss drugs aren’t new, but in recent years, the introduction of semaglutide has changed the game when it comes to treating obesity with medicine as opposed to other methods. now, a new study shows that another drug is on the horizon—and it shows nearly double the efficacy rate of both wegovy and ozempic. the drug in question, tirzepatide, is a dual gip and glp-1 receptor agonist that works by tweaking certain hormones involved in insulin secretion and improving the body’s ability to use insulin. it can also improve lipid metabolism, reduce appetite, and reduce gastric emptying.
dr. sean wharton, an internal medicine physician specializing in obesity and type 2 diabetes, and assistant professor at the university of toronto, believes that while there are effective drugs on the market, the introduction of tirzepatide can make it even easier for people living with obesity to get what they need to manage their chronic condition.
“it gives a great number of options,” he said, noting that the current options, while viable for many, don’t always work for everybody.

the tirzepatide study

over the course of roughly 72 weeks, eli lilly and company conducted a study on tirzepatide, brand name zepbound, to see how it compared to the semaglutide weight loss drugs.

related stories

wegovy approved for lowered risk of heart attack: what it means for people living with obesity and heart disease
wegovy is giving people living with obesity and those at risk of heart attack a new therapeutic option that will tackle both.
while there are current therapies available for people living with obesity and heart disease, the introduction of a one-step drug for both can make living with both conditions much more manageable, both physically and mentally.

obesity matters wellness workshop: embracing wellness beyond the scale
the wellness workshops and support sessions are designed to give people confidence and empower them so they can start their own path to better health.
obesity matters has developed a series of 12 wellness workshops starting this fall to bring wellness resources and experts free of charge to all people through informative and actionable virtual gatherings.
story continues below
the surmount-5 phase 3b trial monitored patients on both semaglutide and tirzepatide and found that at the end of the trial, tirzepatide led to a 47 per cent greater weight loss than semaglutide.
regarding how much weight was lost, in the tirzepatide group, people who had obesity lost at least 25 per cent. in contrast, in the semaglutide group, only 16.1 per cent of weight loss was noted, akin to 50.3 pounds and 33.1 pounds, respectively.
the results mark a new era in weight loss drugs coming in on the heels of the semaglutide craze, giving people living with obesity another option that offers more weight loss in the same time frame.
the drug was also considered as safe as others on the market in the trial.
“the trial gave us more than three years of safety data, and what we know is that during this time frame, the safety was the exact same in the three-year as it was in the one-year,” said dr. wharton.

what this means for obesity and type 2 diabetes patients

semaglutide medications, including wegovy and ozempic, are still as effective and safe as they have always been. however, the introduction of tirzepatide can give patients another route to take if these drugs don’t work as intended.
“it gives a greater number of options because the main molecule that we have now doesn’t work in everybody, so there’s patients who continue to struggle with their obesity, with their cravings, with their hunger,” said dr. wharton. “they’re on the current product and on this new product now, those same people may be able to get a switch over study and may be able to get the relief.”
powered by
obesity canada
story continues below
the drug may also have the potential to act as a treatment or preventative health measure for type 2 diabetes.
“we also know that this medication and the current medications are really great diabetes and prediabetes drugs,” said dr. wharton. “so, in essence, if you have prediabetes or family risk of type 2 diabetes and you don’t want diabetes and you take these medications, you will not get diabetes.”
the promising drug now has to go through the process of being approved for use by canadians by health canada. for now, patients will have to wait for that access, and according to dr. wharton, that could be far off, considering the ones that are available are still hard to access due to cost.
“it’s all dependant on government involvement, patient advocacy,” he said. “without the advocacy to try and get access to care, i think this will remain in the hands of the rich.”
dr. wharton notes that people will “have to let their voices be heard” so that the government can move forward with new drugs like tirzepatide, make them affordable for canadians, and improve the lives of people living with obesity across the country.

obesity in canada

the number of canadians living with obesity has risen significantly in the last two decades, and those numbers are expected to continue growing. according to statistics canada, roughly one in five people were living with obesity in 2003. in 2022, that number was closer to one in three.
powered by
obesity matters
story continues below
the understanding of the chronic disease has improved as more study has gone into it, but medical professionals still haven’t cracked the code in regard to why it develops and why it’s so challenging to address.
“there’s a lot of research and science behind it and genes, what turns these genes on, and how it all happened, but we don’t really know (why),” said dr. wharton. “we don’t really have all the understanding of why some people have obesity, and others don’t, right?”
dr. wharton goes on to note that while they know much more than ever, “we’re also humbled by the fact that we don’t truly understand the multiple levels that really result in elevated weight versus someone who has a lower weight.”
without an adequate understanding of the disease, it’s challenging to create new medical interventions. however, as research continues to progress, the development of new drugs to treat obesity will progress as well.
angelica bottaro
angelica bottaro

angelica bottaro is the lead editor at healthing.ca, and has been content writing for over a decade, specializing in all things health. her goal as a health journalist is to bring awareness and information to people that they can use as an additional tool toward their own optimal health.

read more about the author

comments

postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. comments may take up to an hour for moderation before appearing on the site. we ask you to keep your comments relevant and respectful. we have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. visit our community guidelines for more information and details on how to adjust your email settings.

you may also like
ozempic insulin injection pen for diabetics and weight loss.
wegovy approved for lowered risk of heart attack: what it means for people living with obesity and heart disease
obesity matters has developed a series of 12 wellness workshops starting this fall to bring wellness resources and experts free of charge to all people through informative and actionable virtual gatherings.
obesity matters wellness workshop: embracing wellness beyond the scale
the obesity matters leadership team, pictured, has worked tirelessly to develop resources to bring unprecedented support to people living with obesity in quebec through the organization's new french division, parlons obésité.
obesity matters launches french division to support and advocate for people in quebec  
a group of cheerful small school kids in canteen, eating lunch and talking.
understanding the childhood obesity epidemic: environment, genetics and education
neda nasseri, product director of benefits at desjardins insurance and advisory board member with obesity matters; rachel atkins, board vice-chair, director of strategy, and patient advocate with obesity matters; and dr. david attalla, internal medicine and obesity medicine physician. (left to right)
the toll of obesity: long-term impact, access to care and insurance support
you may also like
ozempic insulin injection pen for diabetics and weight loss.
wegovy approved for lowered risk of heart attack: what it means for people living with obesity and heart disease
obesity matters has developed a series of 12 wellness workshops starting this fall to bring wellness resources and experts free of charge to all people through informative and actionable virtual gatherings.
obesity matters wellness workshop: embracing wellness beyond the scale
the obesity matters leadership team, pictured, has worked tirelessly to develop resources to bring unprecedented support to people living with obesity in quebec through the organization's new french division, parlons obésité.
obesity matters launches french division to support and advocate for people in quebec  
a group of cheerful small school kids in canteen, eating lunch and talking.
understanding the childhood obesity epidemic: environment, genetics and education
you may also like
ozempic insulin injection pen for diabetics and weight loss.
wegovy approved for lowered risk of heart attack: what it means for people living with obesity and heart disease
obesity matters has developed a series of 12 wellness workshops starting this fall to bring wellness resources and experts free of charge to all people through informative and actionable virtual gatherings.
obesity matters wellness workshop: embracing wellness beyond the scale